Connect your AI

Nektar Therapeutics NKTR Book value per share

Book value per share at other companies

AmgenAMGN

$16.89+47.2%

Regeneron PharmaceuticalsREGN

$291.77+10.4%

ImmunityBio, Inc.IBRX

-$0.85-22.2%

ImmunomeIMNM

$5.20+34.5%

Vera TherapeuticsVERA

$6.99-16.8%

Iovance Biotherapeutics, Inc.IOVA

$1.72-27.5%

Other financials

Income statement

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Calculated from Nektar Therapeutics’s reported figures.

total stockholders equity/weighted shares diluted=$23.29

Based on the most recent quarter.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nektar Therapeutics's book value per share?: Nektar Therapeutics (NKTR) reported book value per share of $23.29 in Q1 2026.
How has Nektar Therapeutics's book value per share changed year-over-year?: Nektar Therapeutics's book value per share increased by 2284.5% year-over-year, from $0.98 to $23.29.
What is the long-term trend for Nektar Therapeutics's book value per share?: Over 5 years (2020 to 2025), Nektar Therapeutics's book value per share has grown at a -2.5% compound annual growth rate (CAGR), from $6.03 to $5.32.
What does book value per share mean?: Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.